Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Gynecologic 2Thoracic 1Sarcoma 1Other solid neoplasm 1

Conditions

Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Breast Neoplasms 1

Interventions

pembrolizumab 7Nivolumab 2Ipilimumab 2Cyclophosphamide 2Cisplatin 2spartalizumab 1regorafenib 1rebastinib 1fludarabine phosphate 1fludarabine 1epacadostat 1enzalutamide 1aldesleukin 1abemaciclib 1Tomography, Optical Coherence 1Talc 1Tablets 1Sirolimus 1Radiofrequency Ablation 1Pemetrexed 1Paclitaxel 1Mitomycin 1Midazolam 1Levoleucovorin 1Leucovorin 1Letrozole 1LY3023414 1Interleukin-2 1Injections 1Immunologic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × rebastinib × Other solid neoplasm × Clear all
NCT03717415 2024-12-27

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Deciphera Pharmaceuticals, LLC

Phase 1/2 Terminated
70 enrolled 24 charts
BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡